![Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fcc11304/MediaObjects/13054_2012_Article_703_Fig2_HTML.jpg)
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective | Critical Care | Full Text
![Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine](https://www.thelancet.com/cms/attachment/f9925654-2075-4af3-810f-b1d854511658/gr1_lrg.jpg)
Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial - The Lancet Respiratory Medicine
![First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet](https://www.thelancet.com/cms/attachment/2112980519/2084195229/gr1.gif)
First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial - The Lancet
![Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse | The Permanente Journal Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse | The Permanente Journal](https://www.thepermanentejournal.org/cms/10.7812/TPP/21.035/asset/2d31ab16-e63c-482e-af1a-7d2a750bdf87/assets/images/large/tpj21035-g009.jpg)
Effect of Immunosuppressive Diseases and Rituximab Infusions on Allowing COVID-19 Infection to Relapse | The Permanente Journal
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g004.jpg)
Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy
![Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy Frontiers | Past, Present, and Future of Rituximab—The World's First Oncology Monoclonal Antibody Therapy](https://www.frontiersin.org/files/Articles/359740/fonc-08-00163-HTML/image_m/fonc-08-00163-g001.jpg)